Previous 10 | Next 10 |
Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) , a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today a...
Nanobiotix S.A. (NBTX) Q1 2022 Earnings Conference Call May 19, 2022 8:00 AM ET Company Participants Kate McNeil – Senior Vice President, Investor Relations Laurent Levy – Co-Founder and Chief Executive Officer Bart Van Rhijn – Chief Financial Officer Conference Call Part...
On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received preliminary feedback from FDA informing development of pivotal Phase II...
On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received preliminary feedback from FDA informing development of pivotal Phase II...
Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, tod...
Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the " Company "), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have been through an extended lean patch, making them ideal candidates for a strong rebound. Verrica ( VRCA ): Approval of its viral skin disease treatment could transform the company into a commerci...
Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) , a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today a...
Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “ Company ”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the presenta...
Data presented at the 2022 Annual Meeting of the American Association of Cancer Research New data from an open-label preclinical study in mice evaluating the changes in immune-related genes induced by multiple combinations of NBTXR3, anti-PD-1, anti-LAG-3, and anti-TIGIT...
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...